Bioidentical HRT Optimization – Part II Clinical Conversations Course Description

Course Credits: Earn up to 15 AMA PRA Category 1 Credits™ and AAFP Prescribed Credits.

Course Price: $1,495

Bioidentical HRT Optimization - Part II Clinical Conversations is a two-day course. There are currently no dates available for this course.

This course utilizes a didactic as well as a case-based approach designed to help physicians and other healthcare providers successfully and competently treat their patients. This is the part two of the NPI BHRT course.  Participation in the first part of this course is a prerequisite for attending part two. 

This intense 2-day mini-residency will review everything about bioidentical hormones, desired levels, and dosing strategies to patients to optimal levels. As opposed to the part one course where the first two hours exists to dynamite health providers out of their conformational bias, the course dives immediately into hormone review, with supporting references, and review the various types of hormones, both good and bad, problematic, and lifesaving, synthetic (non-human) vs. pharmaceutical bioidentical (human identical) vs. compounded (human identical but not FDA tested or approved). Given that this is a “BHRT” course, not much time will be spent on the difference between these two types of hormones, and there will be less emphasis on the “bad” hormones – like medroxyprogesterone. Learners will gain more confidence in their knowledge base and ability to meet the needs of at the point of care. The course integrates concepts of peer-reviewed literature-based medicine throughout the content. Learners will review monitoring and adjusting HRT through didactic lecture focusing on a scrupulous and up-to-date literature review. A simplified dosing strategy for most hormones will be covered. Learning will be facilitated by participant “show and tell” as well as patient-based learning exercises, didactic presentations, case studies, and open discussions. We will re-emphasize the difference between normal and optimal levels of hormones based on the medical literature and actual patient examples. 

Day one will encompass a brief review of material previously presented, with updated references. New topics will also be presented, including adrenal insufficiency, and the possible functional origins of “long COVID” syndrome. There will also be an extensive review of thyroid hormones, plus cases that involve laboratory evaluation, prescribing, adjusting, troubleshooting, and discussing various hormone therapies for different scenarios for both men and women.

Day two features a “show and tell” segment where learners will review labs of anonymous patients to see if they can assess what is occurring. More cases that involve laboratory evaluation, prescribing, adjusting, troubleshooting, and discussion of various hormone therapies for different scenarios for both men and women will be covered.

Throughout the course, the practice of hormone replacement therapy will be based on peer-reviewed medical research and a wealth of clinical experience. This part two course, which is taught subsequently to part one (“Mastering Protocols for Optimization of HRT”), forms the basis of the most comprehensive foundational framework taught on evidence-based medicine principles of hormone and foundational optimization.

Although most providers are fully aware of the need to replace hormones in cases of sub-normal hormone levels, most have not been trained to optimize hormone levels if the baseline hormone level is “normal.” Prior to part one of this course, learners frequently inquire why a patient is treated with various hormones when the baseline lab test indicates “normal.” Even after part one, some learners have problems with optimization. The medical literature supports that normal is not necessarily optimal, as well as the reverse “optimal is not necessarily normal.” A multitude of studies support optimization of all hormones regardless of the baseline levels, both for maintenance of the quality of life and for future health benefits. Many of these have been covered in part one. We will review that the medical literature demonstrates that optimization of hormones results in relief of symptoms, improvement in well-being, and a decrease in morbidity and mortality by attaining levels in the upper range of normal. Providers must understand both the need and benefit for optimization, what levels are considered to be optimal, as well as have command of the literature that supports it. This course will amplify on and further support all of the concepts of optimizing hormones.